Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease

Neurologix, Inc. (NRGX) announced today several new results from the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee. Recently completed analysis of new data showed patients treated with NLX-P101 had significantly increased "ON" times, or periods in which the symptoms of PD are best controlled, compared to sham subjects over the course of 12 months following treatment. Significant reductions in complications due to medical therapy were also seen following treatment with NLX-P101. These new findings, which demonstrate patients treated with NLX-P101 maintained statistically significant, positive, long-term improvements at 12 months, were included in today's presentation of results from the landmark Phase 2 trial by Matthew J. During, M.D., D.Sc., one of the scientific co-founders of Neurologix.